Skip to content
10-Q

Quarterly Report

Adhera Therapeutics, Inc.

0001493152-23-018516

← back to feed
Filed
May 22, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 22, 2023 3.49M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$310K
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$216K
Stockholders Equity Q1 2023 · Mar 31, 2023 −$23.09M
Stockholders Equity Q1 2023 · Dec 31, 2022 −$22.19M
Stockholders Equity Q1 2023 · Mar 31, 2022 −$25.5M
Stockholders Equity Q1 2023 · Dec 31, 2021 −$25.11M
Current Liabilities Q1 2023 · Mar 31, 2023 $23.2M
Current Liabilities Q1 2023 · Dec 31, 2022 $22.27M
Total Liabilities Q1 2023 · Mar 31, 2023 $23.2M
Total Liabilities Q1 2023 · Dec 31, 2022 $22.27M
Current Assets Q1 2023 · Mar 31, 2023 $104K
Current Assets Q1 2023 · Dec 31, 2022 $79K
Total Assets Q1 2023 · Mar 31, 2023 $104K
Total Assets Q1 2023 · Dec 31, 2022 $79K
Eps Basic Q1 2023 · Mar 31, 2023 −$0.29
Eps Basic restated Q1 2023 · Mar 31, 2022 −$0.51
Net Income Q1 2023 · Mar 31, 2023 −$886K
Net Income Q1 2023 · Mar 31, 2022 −$74K
Operating Income Q1 2023 · Mar 31, 2023 −$353K
Operating Income Q1 2023 · Mar 31, 2022 −$260K